275 related articles for article (PubMed ID: 27128108)
1. Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
Kim SH; Kim HJ
Curr Opin Neurol; 2016 Jun; 29(3):372-80. PubMed ID: 27128108
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
5. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
6. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
[TBL] [Abstract][Full Text] [Related]
7. What You Need to Know About AQP4, MOG, and NMOSD.
Prasad S; Chen J
Semin Neurol; 2019 Dec; 39(6):718-731. PubMed ID: 31847043
[TBL] [Abstract][Full Text] [Related]
8. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
Ungureanu A; de Seze J; Ahle G; Sellal F
Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
Front Immunol; 2020; 11():1188. PubMed ID: 32625206
[TBL] [Abstract][Full Text] [Related]
11. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
13. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica spectrum disorders: still evolving and broadening.
Fujihara K
Curr Opin Neurol; 2019 Jun; 32(3):385-394. PubMed ID: 30893099
[TBL] [Abstract][Full Text] [Related]
15. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
16. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
de Seze J
Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
[TBL] [Abstract][Full Text] [Related]
18. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
19. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
[TBL] [Abstract][Full Text] [Related]
20. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
